Khandan Keyomarsi Selected Research

Elafin

6/2015	Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
1/2014	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
1/2013	Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.
9/2010	The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.
12/2007	Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Khandan Keyomarsi Research Topics

Disease

63	Neoplasms (Cancer) 01/2022 - 11/2002
55	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2002
9	Carcinogenesis 01/2016 - 07/2003
8	Triple Negative Breast Neoplasms 06/2022 - 08/2015
8	Genomic Instability 06/2010 - 07/2003
7	Ovarian Neoplasms (Ovarian Cancer) 06/2022 - 04/2004
7	Neoplasm Metastasis (Metastasis) 02/2016 - 11/2002
5	Carcinoma (Carcinomatosis) 01/2014 - 04/2004
2	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2017
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 10/2008
2	Leiomyosarcoma 01/2017 - 10/2008
2	Retinoblastoma (Glioblastoma, Retinal) 09/2010 - 10/2006
2	Polyploidy 06/2010 - 05/2004
2	Chromosomal Instability (Chromosome Stability) 06/2010 - 05/2004
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Salivary Gland Neoplasms (Salivary Gland Cancer) 05/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2019
1	Inflammatory Breast Neoplasms 02/2017
1	Disease Progression 01/2017
1	Squamous Cell Carcinoma of Head and Neck 01/2017
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2014
1	Cystadenoma 01/2014
1	Transitional Cell Carcinoma 04/2012
1	Urinary Bladder Neoplasms (Bladder Cancer) 04/2012

Drug/Important Bio-Agent (IBA)

40	Cyclin EIBA 05/2021 - 11/2002
20	Protein Isoforms (Isoforms)IBA 10/2018 - 11/2002
15	Proteins (Proteins, Gene)FDA Link 01/2018 - 03/2004
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2004
9	Phosphotransferases (Kinase)IBA 04/2021 - 04/2004
7	Hormones (Hormone)IBA 01/2022 - 08/2005
7	Biological ProductsIBA 05/2020 - 07/2003
6	Pharmaceutical PreparationsIBA 01/2022 - 01/2003
5	Estrogen ReceptorsIBA 01/2019 - 02/2010
5	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2018 - 03/2004
5	Cyclin-Dependent Kinase 2IBA 01/2016 - 03/2004
5	ElafinIBA 06/2015 - 12/2007
5	CyclinsIBA 06/2013 - 07/2003
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2022 - 01/2017
4	palbociclibIBA 01/2022 - 01/2017
4	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 08/2005
4	Phenobarbital (Luminal)FDA Link 01/2018 - 06/2009
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 10/2008
3	Cyclin-Dependent Kinase 4IBA 01/2022 - 01/2017
3	LigandsIBA 01/2021 - 01/2014
3	Pancreatic Elastase (Elastase)IBA 01/2021 - 07/2003
3	Cytostatic AgentsIBA 01/2020 - 09/2010
3	adavosertibIBA 12/2018 - 01/2017
3	EnzymesIBA 01/2018 - 01/2003
3	Small Interfering RNA (siRNA)IBA 03/2014 - 10/2006
3	RoscovitineIBA 01/2012 - 10/2008
3	Estrogen Receptor Modulators (Antiestrogen)IBA 08/2007 - 01/2004
2	Perilipin-2IBA 01/2021 - 01/2016
2	dinaciclibIBA 01/2018 - 08/2015
2	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2018
2	Histones (Histone)IBA 01/2018 - 08/2006
2	Aromatase InhibitorsIBA 12/2017 - 02/2010
2	Letrozole (Femara)FDA LinkGeneric 12/2017 - 02/2010
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2016 - 01/2016
2	StaurosporineIBA 10/2013 - 10/2006
2	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2011 - 01/2006
2	Cell ExtractsIBA 04/2011 - 03/2004
2	Chymotrypsin FDA Link 04/2011 - 01/2006
2	Cyclin D1IBA 06/2009 - 11/2002
2	Lovastatin (Mevacor)FDA LinkGeneric 08/2008 - 01/2006
1	Aurora KinasesIBA 01/2022
1	Aurora Kinase AIBA 01/2022
1	Taxoids (Taxanes)IBA 01/2021
1	AnthracyclinesIBA 01/2021
1	taxaneIBA 01/2021
1	Biological FactorsIBA 03/2020
1	7-hydroxystaurosporine (UCN 01)IBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 12/2018
1	ChromatinIBA 01/2018
1	niraparibIBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	Drug CombinationsIBA 01/2017
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 02/2016
1	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 02/2016
1	Estrogen Receptor alphaIBA 01/2016
1	ATP Citrate (pro-S)-Lyase (Citrate Synthase, ATP)IBA 01/2016
1	human ERBB2 proteinIBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Carrier Proteins (Binding Protein)IBA 01/2016
1	Epirubicin (Ellence)FDA LinkGeneric 08/2015
1	indole-3-carbinolIBA 01/2014
1	alkoxyl radicalIBA 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 01/2014
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2014
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 09/2013
1	Claudin-1IBA 06/2013
1	Messenger RNA (mRNA)IBA 06/2013
1	Indicators and Reagents (Reagents)IBA 01/2013
1	Antigen-Antibody Complex (Immune Complex)IBA 04/2012

Therapy/Procedure

27	Therapeutics 06/2022 - 01/2003
10	Drug Therapy (Chemotherapy) 01/2021 - 08/2005
2	Neoadjuvant Therapy 01/2021 - 12/2017
1	Aftercare (After-Treatment) 12/2017
1	Radiotherapy 01/2017
1	Investigational Therapies (Experimental Therapy) 01/2016